S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
S&P 500   4,288.41 (-1.13%)
DOW   33,697.57 (-0.91%)
QQQ   354.98 (-1.29%)
AAPL   172.73 (-1.90%)
MSFT   311.25 (-1.98%)
META   298.36 (-0.82%)
GOOGL   127.41 (-2.82%)
AMZN   127.02 (-3.24%)
TSLA   247.43 (+0.18%)
NVDA   422.20 (+0.00%)
NIO   8.54 (+2.28%)
BABA   86.24 (-1.12%)
AMD   96.33 (-1.08%)
T   14.97 (-0.60%)
F   12.51 (-0.56%)
MU   68.56 (-0.03%)
CGC   0.97 (+2.87%)
GE   110.24 (-1.32%)
DIS   80.31 (-0.86%)
AMC   8.27 (+1.60%)
PFE   32.68 (-0.91%)
PYPL   58.98 (+0.20%)
NFLX   383.51 (-0.34%)
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Forecast, Price & News

$2.47
+0.06 (+2.49%)
(As of 11:28 AM ET)
Compare
Today's Range
$2.38
▼
$2.56
50-Day Range
$2.41
▼
$5.07
52-Week Range
$2.37
▼
$9.49
Volume
659,617 shs
Average Volume
2.22 million shs
Market Capitalization
$316.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Seres Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
467.1% Upside
$13.67 Price Target
Short Interest
Healthy
15.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
1.01mentions of Seres Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.14) to ($1.58) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

325th out of 961 stocks

Pharmaceutical Preparations Industry

137th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

MCRB stock logo

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Price History

MCRB Stock News Headlines

September 24, 2023 | americanbankingnews.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Recommendation of "Moderate Buy" from Analysts
September 11, 2023 | msn.com
Seres: VOWST Is A Great Product But Commercialization Prospects Unclear Due To Very High Price
September 26, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 7, 2023 | finance.yahoo.com
Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 1, 2023 | msn.com
Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
August 9, 2023 | markets.businessinsider.com
Seres Therapeutics (MCRB) Receives a Sell from Goldman Sachs
August 9, 2023 | finance.yahoo.com
Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel
August 8, 2023 | msn.com
Seres Therapeutics' Q2 Revenues Top Estimates; Reports Encouraging VOWST Early Commercial Uptake
September 26, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
August 8, 2023 | finance.yahoo.com
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
August 8, 2023 | benzinga.com
Earnings Outlook For Seres Therapeutics
August 8, 2023 | finance.yahoo.com
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 3, 2023 | msn.com
Seres Therapeutics: VOWST's Time To Shine
August 1, 2023 | finance.yahoo.com
Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
August 1, 2023 | finance.yahoo.com
Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
July 25, 2023 | markets.businessinsider.com
'Walk Away From It': Jim Cramer On This US Telecom Service Provider
July 10, 2023 | seekingalpha.com
Seres Therapeutics: Microbiome Therapeutics Amid High Operational Costs And Uncertain Profitability Path
July 7, 2023 | finance.yahoo.com
Seres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years ago
June 21, 2023 | finance.yahoo.com
Seres Therapeutics Named to TIME100 Most Influential Companies List
June 17, 2023 | finance.yahoo.com
Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
June 5, 2023 | msn.com
Seres, Nestle Health announce US launch of c. diff therapy Vowst
June 5, 2023 | finance.yahoo.com
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
June 2, 2023 | finance.yahoo.com
Seres Therapeutics to Present at Jefferies Healthcare Conference
May 30, 2023 | finance.yahoo.com
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
May 23, 2023 | fool.com
Seres Therapeutics (NASDAQ: MCRB)
May 23, 2023 | seekingalpha.com
Seres Q1 Earnings: Major News For Investors
May 22, 2023 | seekingalpha.com
Seres Therapeutics: Still Work To Do Before Realizing Its Potential
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
CUSIP
N/A
CIK
1609809
Web
www.serestherapeutics.com
Phone
(617) 945-9626
Fax
N/A
Employees
431
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+467.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-250,160,000.00
Net Margins
-3,509.50%
Pretax Margin
-117.68%
Return on Equity
-1,155.47%
Return on Assets
-45.89%

Debt

Debt-to-Equity Ratio
4.45
Current Ratio
3.23
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$7.13 million
Price / Sales
43.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
26.78

Miscellaneous

Outstanding Shares
128,210,000
Free Float
122,051,000
Market Cap
$308.99 million
Optionable
Optionable
Beta
2.63
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 47)
    Pres, CEO & Director
    Comp: $1.07M
  • Mr. David A. Arkowitz M.B.A. (Age 62)
    Exec. VP, CFO & Head of Bus. Devel.
    Comp: $670.02k
  • Dr. Matthew R. Henn Ph.D. (Age 48)
    Exec. VP & Chief Scientific Officer
    Comp: $643.83k
  • Ms. Paula A. Cloghessy SHRM-SCP (Age 51)
    SPHR, Exec. VP & Chief People Officer
    Comp: $521.27k
  • Dr. Lisa von Moltke M.D. (Age 64)
    Exec. VP & Chief Medical Officer
    Comp: $706.14k
  • Dr. David S. Ege Ph.D. (Age 48)
    Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 68)
    J.D., Chief Legal Officer, Exec. VP & Sec.
  • Dr. Teresa L. Young Ph.D. (Age 56)
    R.Ph., Exec. VP and Chief Commercial & Strategy Officer
  • Ms. Caroline Holda
    Assistant Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.

What is Seres Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for Seres Therapeutics' stock. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they anticipate the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 467.1% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2023?

Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB shares have decreased by 57.0% and is now trading at $2.41.
View the best growth stocks for 2023 here.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MCRB earnings forecast.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by $0.19. The biotechnology company had revenue of $126.50 million for the quarter, compared to analysts' expectations of $125.67 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 1,155.47% and a negative net margin of 3,509.50%. The firm's quarterly revenue was up 10441.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.70) earnings per share.

What ETF holds Seres Therapeutics' stock ?

Simplify Propel Opportunities ETF holds 550,626 shares of MCRB stock, representing 2.57% of its portfolio.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (6.68%), BlackRock Inc. (5.84%), Geode Capital Management LLC (1.53%), Jennison Associates LLC (1.09%), Point72 Asset Management L.P. (0.80%) and Handelsbanken Fonder AB (0.78%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $2.41.

How much money does Seres Therapeutics make?

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $308.99 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Seres Therapeutics have?

The company employs 431 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -